Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications.Cardiovascular drugs and therapy · 2026
   Review
2. Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy.Journal of clinical medicine · 2024
   Review
3. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").Clinical research in cardiology : official journal of the German Cardiac Society · 2023
   Article
4. Optimal management of patients after acute coronary syndrome.European heart journal supplements : journal of the European Society of Cardiology · 2023
   Article
5. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study.Atherosclerosis plus · 2022
   Article
6. [Lipid lowering: new agents and new concepts].Herz · 2022
   Review
7. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?Current atherosclerosis reports · 2021
   Review

Corrections and comments

• Comment on
  Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study.2021

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as